Pharmacokinetics of Subcutaneous Itepekimab Injection With an Autoinjector Device and Prefilled Syringe in Healthy Participants.
Phase 1
autoinjector
itepekimab
pharmacokinetics
prefilled syringe
Journal
Clinical pharmacology in drug development
ISSN: 2160-7648
Titre abrégé: Clin Pharmacol Drug Dev
Pays: United States
ID NLM: 101572899
Informations de publication
Date de publication:
23 Sep 2024
23 Sep 2024
Historique:
received:
02
03
2024
accepted:
13
08
2024
medline:
23
9
2024
pubmed:
23
9
2024
entrez:
23
9
2024
Statut:
aheadofprint
Résumé
Itepekimab, a monoclonal antibody against interleukin-33, has demonstrated clinical utility in previous studies in patients with asthma and chronic obstructive pulmonary disease. An autoinjector (AI) has been developed for administering itepekimab to facilitate further development. This study compared pharmacokinetics of single 300-mg itepekimab subcutaneous administration via an AI versus a prefilled syringe (PFS). Of 90 healthy volunteers enrolled in this Phase 1, parallel-design, randomized study and stratified by body weight (50 to <70 kg, ≥70 to <80 kg, ≥80 to 100 kg) and injection site (abdomen, thigh, or arm), 84 completed the study. Systemic exposure of itepekimab was similar for both groups. Point estimates for geometric mean ratios of pharmacokinetic parameters for AI versus PFS groups were 1.01 for maximum serum concentration, 1.06 for area under the serum concentration-time curve to the last quantifiable concentration, and 1.04 for area under the serum concentration-time curve extrapolated to infinity. The exposure was similar for both devices in each body weight and injection site subgroup. Overall, systemic exposure of 300-mg single-dose itepekimab in healthy participants was comparable when administered subcutaneously via an AI device and PFS, with an acceptable safety profile in both device groups.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Sanofi and Regeneron Pharmaceuticals, Inc.
Informations de copyright
© 2024 The Author(s). Clinical Pharmacology in Drug Development published by Wiley Periodicals LLC on behalf of American College of Clinical Pharmacology.
Références
Donovan C, Hansbro PM. IL‐33 in chronic respiratory disease: from preclinical to clinical studies. ACS Pharmacol Transl Sci. 2020;3(1):56‐62.
Calderon AA, Dimond C, Choy DF, et al. Targeting interleukin‐33 and thymic stromal lymphopoietin pathways for novel pulmonary therapeutics in asthma and COPD. Eur Respir Rev. 2023;32(167):220144.
Allinne J, Scott G, Lim WK, et al. IL‐33 blockade affects mediators of persistence and exacerbation in a model of chronic airway inflammation. J Allergy Clin Immunol. 2019;144(6):1624‐1637.e10.
Rabe KF, Celli BR, Wechsler ME, et al. Safety and efficacy of itepekimab in patients with moderate‐to‐severe COPD: a genetic association study and randomised, double‐blind, phase 2a trial. Lancet Respir Med. 2021;9(11):1288‐1298.
Wechsler ME, Ruddy MK, Pavord ID, et al. Efficacy and safety of itepekimab in patients with moderate‐to‐severe asthma. N Engl J Med. 2021;385(18):1656‐1668.
Kosloski MP, Kalliolias GD, Xu CR, et al. Pharmacokinetics and pharmacodynamics of itepekimab in healthy adults and patients with asthma: phase I first‐in‐human and first‐in‐patient trials. Clin Transl Sci. 2022;15(2):384‐395.
Borrás‐Blasco J, Gracia‐Pérez A, Rosique‐Robles JD, Casterá MD, Abad FJ. Acceptability of switching adalimumab from a prefilled syringe to an autoinjection pen. Expert Opin Biol Ther. 2010;10(3):301‐307.
Cohen YZ, Zhang X, Xia B, et al. Pharmacokinetics of subcutaneous dupilumab injection with an autoinjector device or prefilled syringe. Clin Pharmacol Drug Dev. 2022;11(5):675‐681.
Li Z, Easton R. Practical considerations in clinical strategy to support the development of injectable drug‐device combination products for biologics. MAbs. 2018;10(1):18‐33.
Hu P, Wang J, Florian J, et al. Systematic review of device parameters and design of studies bridging biologic‐device combination products using prefilled syringes and autoinjectors. AAPS J. 2020;22(2):52.
Zou P, Wang F, Wang J, Lu Y, Tran D, Seo SK. Impact of injection sites on clinical pharmacokinetics of subcutaneously administered peptides and proteins. J Control Release. 2021;336:310‐321.
van den Bemt BJF, Gettings L, Domańska B, Bruggraber R, Mountian I, Kristensen LE. A portfolio of biologic self‐injection devices in rheumatology: how patient involvement in device design can improve treatment experience. Drug Deliv. 2019;26(1):384‐392.
Roy A, Geetha RV, Magesh A, Vijayaraghavan R, Ravichandran V. Autoinjector – a smart device for emergency cum personal therapy. Saudi Pharm J. 2021;29(10):1205‐1215.
Phillips JT, Fox E, Grainger W, Tuccillo D, Liu S, Deykin A. An open‐label, multicenter study to evaluate the safe and effective use of the single‐use autoinjector with an Avonex® prefilled syringe in multiple sclerosis subjects. BMC Neurol. 2011;11:126.
Ward LG, Aton SS. Impact of an interchange program to support use of insulin pens. Am J Health Syst Pharm. 2011;68(14):1349‐1352.
Verdun di Cantogno E, Russell S, Snow T. Understanding and meeting injection device needs in multiple sclerosis: a survey of patient attitudes and practices. Patient Prefer Adherence. 2011;5:173‐180.
Lon HK, Cheng L, Nudurupati S, et al. Pharmacokinetic comparability of risankizumab formulations in prefilled syringe and auto‐injector for subcutaneous injection. Clin Ther. 2021;43(3):629‐636.
Hendrikx J, Haanen J, Voest EE, Schellens JHM, Huitema ADR, Beijnen JH. Fixed dosing of monoclonal antibodies in oncology. Oncologist. 2017;22(10):1212‐1221.
Li Z, Radin A, Li M, et al. Pharmacokinetics, pharmacodynamics, safety, and tolerability of dupilumab in healthy adult subjects. Clin Pharmacol Drug Dev. 2020;9(6):742‐755.
KHaM RJ. Improving the outcomes of biopharmaceutical delivery via the subcutaneous route by understanding the chemical, physical and physiological properties of the subcutaneous injection site. J Control Release. 2014;182:22‐32.
Fishbane S, Pannier A, Liogier X, Jordan P, Dougherty FC, Reigner B. Pharmacokinetic and pharmacodynamic properties of methoxy polyethylene glycol‐epoetin beta are unaffected by the site of subcutaneous administration. J Clin Pharmacol. 2007;47(11):1390‐1397.
Richter WF, Bhansali SG, Morris ME. Mechanistic determinants of biotherapeutics absorption following SC administration. AAPS J. 2012;14(3):559‐570.